Pricing pressures and Middle East unrest hit GSK profits

Article Date: 26/04/2012 07:45
Pricing pressures and Middle East unrest hit GSK profits

Vacancy Search

Quick job search

Advanced Search

Latest News

GSK's diabetes drug Tanzeum gets FDA OK

GSK's diabetes drug Tanzeum gets FDA OK

US drug spending growth returned in 2013: report

US drug spending growth returned in 2013: report

Tough 2013 for Boehringer but future looks bright

Tough 2013 for Boehringer but future looks bright

NICE nod for Firmagon's prostate cancer drug

NICE nod for Firmagon's prostate cancer drug

Merck & Co gets FDA OK for allergy treatment Grastek

Merck & Co gets FDA OK for allergy treatment Grastek

Poor uptake of NHS health checks sparks concern

Poor uptake of NHS health checks sparks concern

EFPIA prepares members for financial disclosure rules

EFPIA prepares members for financial disclosure rules

Interview – Overnight sensation Intercept settles down for hard yards

Ask Intercept Pharmaceuticals chief executive Mark Pruzanski whether he expected his company to become the poster child of the biotech bull market, and he will say it took him off guard.

Back to the drawing board for Boehringer and Presidio in hep C

Just how tough competing in hepatitis C has become is perfectly illustrated by Boehringer Ingelheim’s exit from the hottest part of this space in March, and the group has recently put more...

End of the road for Cytos after asthma flop

End of the road for Cytos after asthma flop
more news